Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorGrillo, Thais Gagno-
Autor(es): dc.creatorda Silva Mazeto Pupo Silveira, Caroline Ferreira-
Autor(es): dc.creatorQuaglio, Ana Elisa Valencise-
Autor(es): dc.creatorde Medeiros Dutra, Renata-
Autor(es): dc.creatorBaima, Julio Pinheiro-
Autor(es): dc.creatorZanati Bazan, Silmeia Garcia-
Autor(es): dc.creatorSassaki, Ligia Yukie-
Data de aceite: dc.date.accessioned2025-08-21T20:57:37Z-
Data de disponibilização: dc.date.available2025-08-21T20:57:37Z-
Data de envio: dc.date.issued2025-04-29-
Data de envio: dc.date.issued2023-05-26-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.4330/wjc.v15.i5.217-
Fonte completa do material: dc.identifierhttps://hdl.handle.net/11449/298246-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/298246-
Descrição: dc.descriptionTumor necrosis factor inhibitors (anti-TNFs) are widely used therapies for the treatment of inflammatory bowel diseases (IBD); however, their administration is not risk-free. Heart failure (HF), although rare, is a potential adverse event related to administration of these medications. However, the exact mechanism of development of HF remains obscure. TNFα is found in both healthy and damaged hearts. Its effects are concentration- and receptor-dependent, promoting either cardio-protection or cardiomyocyte apoptosis. Experimental rat models with TNF α receptor knockout showed increased survival rates, less reactive oxygen species formation, and improved diastolic left ventricle pressure. However, clinical trials employing anti-TNF therapy to treat HF had disappointing results, suggesting abolishment of the cardioprotective properties of TNFα, making cardiomyocytes susceptible to apoptosis and oxidation. Thus, patients with IBD who have risk factors should be screened for HF before initiating anti-TNF therapy. This review aims to discuss adverse events associated with the administration of anti-TNF therapy, with a focus on HF, and propose some approaches to avoid cardiac adverse events in patients with IBD.-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School São Paulo State University, Botucatu-
Descrição: dc.descriptionDepartment of Biophysics and Pharmacology Institute of Biosciences São Paulo State University, Botucatu-
Descrição: dc.descriptionDepartment of Internal Medicine Medical School São Paulo State University, Botucatu-
Descrição: dc.descriptionDepartment of Biophysics and Pharmacology Institute of Biosciences São Paulo State University, Botucatu-
Formato: dc.format217-228-
Idioma: dc.languageen-
Relação: dc.relationWorld Journal of Cardiology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectAdverse event-
Palavras-chave: dc.subjectHeart failure-
Palavras-chave: dc.subjectInflammatory bowel disease-
Palavras-chave: dc.subjectTNFα receptor-
Palavras-chave: dc.subjectTumor necrosis factor inhibitors-
Título: dc.titleAcute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: A review of the literature-
Tipo de arquivo: dc.typevídeo-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.